DK172034B1 - 4-OH-quinolincarboxylsyrederivater, deres fremstilling, mellemprodukter ved deres fremstilling samt lægemidler med indhold deraf - Google Patents

4-OH-quinolincarboxylsyrederivater, deres fremstilling, mellemprodukter ved deres fremstilling samt lægemidler med indhold deraf Download PDF

Info

Publication number: DK172034B1
Authority: DK; Denmark
Prior art keywords: formula; compound; give; carbon atoms; group
Prior art date: 1985-07-25

Application number

DK351886A

Other languages

Danish (da)

English (en)

Other versions

DK351886A (da

DK351886D0 (da

Inventor

Francois Clemence

Odile Le Martret

Francoise Delevallee

Original Assignee

Roussel Uclaf

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-07-25

Filing date

1986-07-24

Publication date

1997-09-22

1986-07-24 Application filed by Roussel Uclaf filed Critical Roussel Uclaf

1986-07-24 Publication of DK351886D0 publication Critical patent/DK351886D0/da

1987-01-26 Publication of DK351886A publication Critical patent/DK351886A/da

1997-09-22 Application granted granted Critical

1997-09-22 Publication of DK172034B1 publication Critical patent/DK172034B1/da

Links

239000003814 drug Substances 0.000 title claims description 10
229940079593 drug Drugs 0.000 title claims description 8
238000002360 preparation method Methods 0.000 title claims description 6
239000000543 intermediate Substances 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims abstract description 112
239000002253 acid Substances 0.000 claims abstract description 31
125000000217 alkyl group Chemical group 0.000 claims abstract description 28
150000003839 salts Chemical class 0.000 claims abstract description 26
150000007513 acids Chemical class 0.000 claims abstract description 20
-1 -SCF3 Chemical group 0.000 claims abstract description 15
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 25
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 16
239000003795 chemical substances by application Substances 0.000 claims description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical group CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims description 7
230000002378 acidificating effect Effects 0.000 claims description 7
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000005843 halogen group Chemical group 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
229910052801 chlorine Inorganic materials 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
125000000335 thiazolyl group Chemical group 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
239000000460 chlorine Substances 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
230000003301 hydrolyzing effect Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
229910052736 halogen Inorganic materials 0.000 abstract 2
150000002367 halogens Chemical class 0.000 abstract 2
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
239000002585 base Substances 0.000 description 19
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
239000000243 solution Substances 0.000 description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
238000000034 method Methods 0.000 description 8
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000013078 crystal Substances 0.000 description 6
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 6
150000003857 carboxamides Chemical class 0.000 description 5
238000010992 reflux Methods 0.000 description 5
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000012043 crude product Substances 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
UNLVJVQEDSDPIN-UHFFFAOYSA-N 2-amino-3-(trifluoromethyl)benzoic acid Chemical compound NC1=C(C(O)=O)C=CC=C1C(F)(F)F UNLVJVQEDSDPIN-UHFFFAOYSA-N 0.000 description 2
SSWGTERYCJZJPQ-UHFFFAOYSA-N 2-chloro-3-methoxypropanoic acid Chemical compound COCC(Cl)C(O)=O SSWGTERYCJZJPQ-UHFFFAOYSA-N 0.000 description 2
DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229910052770 Uranium Inorganic materials 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
238000006266 etherification reaction Methods 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000002198 insoluble material Substances 0.000 description 2
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
238000002955 isolation Methods 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
239000008101 lactose Substances 0.000 description 2
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
WXPLRSVMGRAIGW-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)acetamide Chemical compound CC(=O)NC1=NC=CS1 WXPLRSVMGRAIGW-UHFFFAOYSA-N 0.000 description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000012286 potassium permanganate Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
AALUTIYNYXEFNT-UHFFFAOYSA-N trimethylsilane hydroiodide Chemical compound C[SiH](C)C.I AALUTIYNYXEFNT-UHFFFAOYSA-N 0.000 description 2
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
SGUVLZREKBPKCE-UHFFFAOYSA-N 1,5-diazabicyclo[4.3.0]-non-5-ene Chemical compound C1CCN=C2CCCN21 SGUVLZREKBPKCE-UHFFFAOYSA-N 0.000 description 1
QUDASMYAQDVGGF-UHFFFAOYSA-N 2-(1,2-dihydroxypropyl)-4-oxo-n-(1,3-thiazol-2-yl)-8-(trifluoromethyl)-1h-quinoline-3-carboxamide Chemical compound CC(O)C(O)C=1NC2=C(C(F)(F)F)C=CC=C2C(=O)C=1C(=O)NC1=NC=CS1 QUDASMYAQDVGGF-UHFFFAOYSA-N 0.000 description 1
UADQHWGURYULKQ-UHFFFAOYSA-N 2-(1-chloro-2-methoxyethyl)-4-oxo-n-(1,3-thiazol-2-yl)-8-(trifluoromethyl)-1h-quinoline-3-carboxamide Chemical compound COCC(Cl)C1=NC2=C(C(F)(F)F)C=CC=C2C(O)=C1C(=O)NC1=NC=CS1 UADQHWGURYULKQ-UHFFFAOYSA-N 0.000 description 1
JPVPJTPNDXUBJK-UHFFFAOYSA-N 2-(1-chloro-2-methoxyethyl)-8-(trifluoromethyl)-3,1-benzoxazin-4-one Chemical compound ClC(COC)C1=NC2=C(C(O1)=O)C=CC=C2C(F)(F)F JPVPJTPNDXUBJK-UHFFFAOYSA-N 0.000 description 1
JYYLQSCZISREGY-UHFFFAOYSA-N 2-amino-4-chlorobenzoic acid Chemical compound NC1=CC(Cl)=CC=C1C(O)=O JYYLQSCZISREGY-UHFFFAOYSA-N 0.000 description 1
LEDCSXQPUGWHKF-UHFFFAOYSA-N 2-prop-1-enyl-8-(trifluoromethyl)-3,1-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)OC(C=CC)=NC2=C1C(F)(F)F LEDCSXQPUGWHKF-UHFFFAOYSA-N 0.000 description 1
KWPQTFXULUUCGD-UHFFFAOYSA-N 3,4,5,7,8,9,10,10a-octahydropyrido[1,2-a][1,4]diazepine Chemical compound C1CCN=CC2CCCCN21 KWPQTFXULUUCGD-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
YTGDOEFTYOODJI-UHFFFAOYSA-N 4-oxo-2-prop-1-enyl-n-(1,3-thiazol-2-yl)-8-(trifluoromethyl)-1h-quinoline-3-carboxamide Chemical compound CC=CC=1NC2=C(C(F)(F)F)C=CC=C2C(=O)C=1C(=O)NC1=NC=CS1 YTGDOEFTYOODJI-UHFFFAOYSA-N 0.000 description 1
GBHLCFAHFCFQKY-UHFFFAOYSA-N 6-chloro-3-(methoxymethyl)-1-(1,3-thiazol-2-ylimino)-3,4-dihydrofuro[3,4-b]quinolin-9-one Chemical compound COCC1OC(C=2C1=NC=1C=C(C=CC=1C=2O)Cl)=NC=1SC=CN=1 GBHLCFAHFCFQKY-UHFFFAOYSA-N 0.000 description 1
YUUGCTFCVMVSJZ-UHFFFAOYSA-N 7-chloro-2-(1,2-dihydroxyethyl)-4-oxo-n-(1,3-thiazol-2-yl)-1h-quinoline-3-carboxamide Chemical compound OCC(O)C1=NC2=CC(Cl)=CC=C2C(O)=C1C(=O)NC1=NC=CS1 YUUGCTFCVMVSJZ-UHFFFAOYSA-N 0.000 description 1
BCHGZKRESNFSNB-UHFFFAOYSA-N 7-chloro-2-(1-chloro-2-methoxyethyl)-3,1-benzoxazin-4-one Chemical compound ClC1=CC=C2C(=O)OC(C(Cl)COC)=NC2=C1 BCHGZKRESNFSNB-UHFFFAOYSA-N 0.000 description 1
CPABPHGMQVXXCX-UHFFFAOYSA-N 7-chloro-2-(1-chloro-2-methoxyethyl)-4-oxo-n-(1,3-thiazol-2-yl)-1h-quinoline-3-carboxamide Chemical compound COCC(Cl)C=1NC2=CC(Cl)=CC=C2C(=O)C=1C(=O)NC1=NC=CS1 CPABPHGMQVXXCX-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
208000027932 Collagen disease Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
CBSOFSBFHDQRLV-UHFFFAOYSA-N N-methylbenzylamine hydrochloride Chemical compound [Cl-].C[NH2+]CC1=CC=CC=C1 CBSOFSBFHDQRLV-UHFFFAOYSA-N 0.000 description 1
206010036030 Polyarthritis Diseases 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
208000000491 Tendinopathy Diseases 0.000 description 1
206010043255 Tendonitis Diseases 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
230000006020 chronic inflammation Effects 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
229960004979 fampridine Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
210000002683 foot Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000007943 implant Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
208000004296 neuralgia Diseases 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
208000030428 polyarticular arthritis Diseases 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
201000004415 tendinitis Diseases 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
208000004371 toothache Diseases 0.000 description 1
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
DNYWZCXLKNTFFI-UHFFFAOYSA-N uranium Chemical compound [U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U][U] DNYWZCXLKNTFFI-UHFFFAOYSA-N 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
WCJYTPVNMWIZCG-UHFFFAOYSA-N xylylcarb Chemical compound CNC(=O)OC1=CC=C(C)C(C)=C1 WCJYTPVNMWIZCG-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Saccharide Compounds (AREA)

DK351886A 1985-07-25 1986-07-24 4-OH-quinolincarboxylsyrederivater, deres fremstilling, mellemprodukter ved deres fremstilling samt lægemidler med indhold deraf DK172034B1 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8511389		1985-07-25
FR8511389A FR2585356B1 (fr)	1985-07-25	1985-07-25	Nouveaux derives de l'acide 4-oh quinoleine carboxylique substitues en 2 par deux fonctions hydroxyle eventuellement etherifiees ou esterifiees, leurs procedes de preparation, les nouveaux intermediaires obtenus, leur application comme medicaments et les compositions les renfermant

Publications (3)

Publication Number	Publication Date
DK351886D0 DK351886D0 (da)	1986-07-24
DK351886A DK351886A (da)	1987-01-26
DK172034B1 true DK172034B1 (da)	1997-09-22

Family

ID=9321642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK351886A DK172034B1 (da)	1985-07-25	1986-07-24	4-OH-quinolincarboxylsyrederivater, deres fremstilling, mellemprodukter ved deres fremstilling samt lægemidler med indhold deraf

Country Status (16)

Country	Link
EP (1)	EP0214004B1 (es)
JP (1)	JPH0710863B2 (es)
KR (1)	KR940003759B1 (es)
AT (1)	ATE87625T1 (es)
AU (1)	AU609377B2 (es)
CA (1)	CA1262903A (es)
DE (1)	DE3688161T2 (es)
DK (1)	DK172034B1 (es)
ES (1)	ES2000739A6 (es)
FI (1)	FI86426C (es)
FR (1)	FR2585356B1 (es)
GR (1)	GR861924B (es)
HU (1)	HU202526B (es)
PT (1)	PT83064B (es)
SU (1)	SU1584749A3 (es)
ZA (1)	ZA865260B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4845105A (en) *	1984-10-30	1989-07-04	Roussel Uclaf	4-OH-quinoline carboxylic acid amides having analgesic and anti-inflammatory activity
US5438344A (en) *	1990-11-05	1995-08-01	Oliva; Anthony	Portable video book
GB9108547D0 (en) *	1991-04-22	1991-06-05	Fujisawa Pharmaceutical Co	Quinoline derivatives
WO1997048707A1 (en) *	1996-06-20	1997-12-24	Smithkline Beecham Plc	4h-3,1-benzoxazin-4-one derivatives and analogs as antiviral agents
JP3337992B2 (ja) *	1997-11-04	2002-10-28	ファイザー製薬株式会社	５−置換ピコリン酸化合物及びその製造方法
JP4804590B1 (ja)	2010-04-14	2011-11-02	帝人テクノプロダクツ株式会社	メタ型全芳香族ポリアミド繊維

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2509728A1 (fr) *	1981-07-17	1983-01-21	Roussel Uclaf	Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
FR2530633A1 (fr) *	1982-06-03	1984-01-27	Roussel Uclaf	Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, et les compositions les renfermant
FR2566405B1 (fr) *	1984-06-25	1986-09-26	Roussel Uclaf	Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus
ZA871658B (en) *	1986-03-27	1987-08-28	Warner-Lambert Company	Chewing gum and confectionery compositions containing a soy flavor enhancer

1985
- 1985-07-25 FR FR8511389A patent/FR2585356B1/fr not_active Expired
1986
- 1986-07-08 HU HU862842A patent/HU202526B/hu not_active IP Right Cessation
- 1986-07-15 ZA ZA865260A patent/ZA865260B/xx unknown
- 1986-07-22 JP JP61170961A patent/JPH0710863B2/ja not_active Expired - Fee Related
- 1986-07-23 GR GR861924A patent/GR861924B/el unknown
- 1986-07-23 SU SU864027833A patent/SU1584749A3/ru active
- 1986-07-24 AT AT86401661T patent/ATE87625T1/de not_active IP Right Cessation
- 1986-07-24 CA CA000514629A patent/CA1262903A/fr not_active Expired
- 1986-07-24 EP EP86401661A patent/EP0214004B1/fr not_active Expired - Lifetime
- 1986-07-24 DE DE86401661T patent/DE3688161T2/de not_active Expired - Fee Related
- 1986-07-24 FI FI863040A patent/FI86426C/fi not_active IP Right Cessation
- 1986-07-24 ES ES8600554A patent/ES2000739A6/es not_active Expired
- 1986-07-24 AU AU60509/86A patent/AU609377B2/en not_active Ceased
- 1986-07-24 DK DK351886A patent/DK172034B1/da not_active IP Right Cessation
- 1986-07-24 KR KR1019860006045A patent/KR940003759B1/ko not_active Expired - Fee Related
- 1986-07-25 PT PT83064A patent/PT83064B/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
JPS6229585A (ja)	1987-02-07
DK351886A (da)	1987-01-26
FR2585356B1 (fr)	1987-10-23
CA1262903A (fr)	1989-11-14
FI863040A7 (fi)	1987-01-26
AU6050986A (en)	1987-01-29
PT83064A (en)	1986-08-01
AU609377B2 (en)	1991-05-02
EP0214004A2 (fr)	1987-03-11
DE3688161D1 (de)	1993-05-06
DK351886D0 (da)	1986-07-24
ATE87625T1 (de)	1993-04-15
FI863040A0 (fi)	1986-07-24
GR861924B (en)	1986-11-25
FI86426B (fi)	1992-05-15
ES2000739A6 (es)	1988-03-16
KR870001206A (ko)	1987-03-12
SU1584749A3 (ru)	1990-08-07
KR940003759B1 (ko)	1994-04-30
FR2585356A1 (fr)	1987-01-30
PT83064B (pt)	1989-02-28
DE3688161T2 (de)	1993-10-14
EP0214004B1 (fr)	1993-03-31
ZA865260B (en)	1987-09-30
JPH0710863B2 (ja)	1995-02-08
FI86426C (fi)	1992-08-25
EP0214004A3 (en)	1989-04-05
HU202526B (en)	1991-03-28
HUT43598A (en)	1987-11-30

Publication	Publication Date	Title
BG60475B2 (bg)	1995-04-28	4-хидрокси-2н-1,2-бензотиазин-3-карбоксамид-1,1-диоксиди, метод за получаването им и лекарствени средства,които ги съдържат
EP0243018B1 (en)	1990-10-24	Thiolactam-n-acetic acid derivatives, their production and use
JPH07267964A (ja)	1995-10-17	新規ｎ−ヘテロ環状チエノチアジンカルボキシアミド、その製造方法及びその使用方法
DK148280B (da)	1985-05-28	Analogifremgangsmaade til fremstilling af thienothiazinderivater
RU2001910C1 (ru)	1993-10-30	Способ получени хинолинового производного
US4299831A (en)	1981-11-10	2-Trifluoromethyl-3-quinoline carboxamides, analgesic and anti-inflammatory compositions and methods employing them
EP0310096B1 (en)	1995-04-19	Novel cyclic anthranilic acid derivatives and process for their preparation
JPH0550512B2 (es)	1993-07-29
FI77030C (fi)	1989-01-10	Foerfarande foer framstaellning av nya i 2-staellningen substituerade 4-hydroxi-3-karboxylsyrakinoliner.
DK172034B1 (da)	1997-09-22	4-OH-quinolincarboxylsyrederivater, deres fremstilling, mellemprodukter ved deres fremstilling samt lægemidler med indhold deraf
JPH03181465A (ja)	1991-08-07	キノリン誘導体
DK168010B1 (da)	1994-01-17	Tetrahydroisoquinolinforbindelser og farmaceutisk middel indeholdende en saadan forbindelse
DE3320102C2 (es)	1992-07-02
DK165981B (da)	1993-02-22	Isoxazolderivater, fremgangsmaade til deres fremstilling og laegemidler indeholdende disse forbindelser
DK170047B1 (da)	1995-05-08	Med basiske heterocycliske grupper substituerede 5-halogen-thienoisothiazol-3(2H)-on-1,1-dioxider og salte deraf, fremgangsmåde til fremstilling af sådanne forbindelser, farmaceutiske præparater indeholdende disse forbindelser og forbindelsernes anvendelse ved fremstilling af lægemidler til behandling af angsttilstande
JPH07252260A (ja)	1995-10-03	新規チエノチアジン誘導体、その製造方法及びその使用方法
US3694450A (en)	1972-09-26	2-substituted-4,5,6,7-tetrahydrobenzothiazole-4-carboxylic acids and their alkyl esters
US3704239A (en)	1972-11-28	Certain thiazole(3,2-a)benzimidazole compounds
CA1317293C (en)	1993-05-04	Substituted 3-phenyl-7h-thiazolo[3,2-b][1,2,4]triazin-7- ones, a process for the preparation thereof, medicaments containing same and the use thereof, and also some intermediates formed in the preparation of the compounds mentioned
Ram et al.	1985	Synthesis of 2‐thiobenzimidazole derivatives as potential antifilarial agents
US3803161A (en)	1974-04-09	2-substituted-4,5,6,7-tetrahydrobenzothiazole-4-carboxylic acids and their alkyl esters
FI70574B (fi)	1986-06-06	Foerfarande foer framstaellning av nya farmaceutiskt anvaendbara derivat av 2-((4-kinolinyl)-amino)-5-fluor- bensoesyra
DK150508B (da)	1987-03-16	Analogifremgangsmaade til fremstilling af benzoxazol- eller benzthiazol-2-carboxylsyreestere eller farmaceutisk acceptable syreadditionssalte eller aminosyre- eller glucuronsyrekonjugatsalte heraf
FI63569C (fi)	1983-07-11	Foerfarande foer framstaellning av farmaceutiskt anvaendbara 6,11-dihydro-11-oxodibenz(b e)oxepinalkylkarboxylsyror och deas estrar
JPH05132483A (ja)	1993-05-28	ベンゾジオキソール誘導体、その製造方法、ロイコトリエンが介在する疾患および症状の治療において使用するためのこの化合物を有する医薬品

Legal Events

Date	Code	Title	Description
1997-09-22	B1	Patent granted (law 1993)
2004-04-05	PBP	Patent lapsed	Country of ref document: DK